Abivax Stock Soars 501.6% on Positive Ulcerative Colitis Trial Results

On July 23, 2025, Abivax's stock experienced a remarkable surge, rising by 501.6% in pre-market trading, reflecting a significant boost in investor confidence.

This surge was primarily driven by the positive Phase 3 trial results for Obefazimod, Abivax's lead drug candidate for ulcerative colitis. The drug achieved its primary goals, demonstrating efficacy with a 19.3% and 13.4% placebo-adjusted response rate.

Investors responded positively to the news, as the successful trial results indicated a promising future for Abivax's treatment for ulcerative colitis. The company's stock price reflected this optimism, with a substantial increase in pre-market trading.